摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氨基甲基苯甲酰胺 | 102562-86-7

中文名称
3-氨基甲基苯甲酰胺
中文别名
——
英文名称
3-(Aminomethyl)benzamide
英文别名
——
3-氨基甲基苯甲酰胺化学式
CAS
102562-86-7
化学式
C8H10N2O
mdl
MFCD07186292
分子量
150.18
InChiKey
HYHLWVJLJXARGY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    237-239 °C (decomp)
  • 沸点:
    316.4±25.0 °C(Predicted)
  • 密度:
    1.172±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    69.1
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2924299090
  • 危险性防范说明:
    P301+P312+P330
  • 危险性描述:
    H302

SDS

SDS:c70fc3f34c535a5699f9ca4b855274e1
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-(Aminomethyl)benzamide
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-(Aminomethyl)benzamide
CAS number: 102562-86-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H10N2O
Molecular weight: 150.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    3-氨基甲基苯甲酰胺盐酸苯甲醚三乙胺氯磷酸二苯酯 作用下, 以 1,4-二氧六环乙酸乙酯 为溶剂, 反应 9.0h, 生成 {(1S,2S)-1-Benzyl-3-[(R)-4-(3-carbamoyl-benzylcarbamoyl)-5,5-dimethyl-thiazolidin-3-yl]-2-hydroxy-3-oxo-propyl}-carbamic acid tert-butyl ester
    参考文献:
    名称:
    一种新型二肽基 HIV 蛋白酶抑制剂,含有别苯诺他汀
    摘要:
    结合别苯去甲司他汀的二肽类似物 [Apns; (2S, 3S) -3amino-2-hydroxy-4-phenylbutyric acid]作为易断键处的过渡态模拟物被设计和合成,希望获得新型 KNI 系列 HIV 蛋白酶抑制剂。前体,N-P2'-3-(2S,3S)-3-(叔丁氧基-羰基)氨基-2-羟基-4-苯基丁酰基)-5,5-二甲基噻唑烷-4-甲酰胺(N-Boc- Apns - Dmt - P2 ') 4a - p 通过合成酮 N - P2 ' - (叔丁氧羰基) - 5, 5 - 二甲基噻唑烷 - 4 - 甲酰胺 (Boc - Dmt - P2 ') 2a - p 的脱保护制备,然后与 (2S, 3S) 3- (叔丁氧羰基) 氨基- 2- 羟基- 4- 苯基丁酸 (N - Boc - Apns - OH) 偶联 3. 脱保护的中间体 4 与 P2 配体的活化羧基偶联以提供目标二肽。在这项工作中,我们在
    DOI:
    10.1002/ardp.200400882
  • 作为产物:
    描述:
    2-methylpropan-2-yl {[(3-cyanophenyl)methyl]amino}methanoate盐酸双氧水 、 sodium hydroxide 作用下, 以 甲醇乙醇 为溶剂, 反应 3.0h, 生成 3-氨基甲基苯甲酰胺
    参考文献:
    名称:
    三环类化合物、其药物组合物及其应用
    摘要:
    本发明公开了一种三环类化合物、其药物组合物及其应用。具体地,本发明公开了一种如式(I)所示的化合物或其药学上可接受的盐。本发明所述的如式(I)所示的化合物或其药学上可接受的盐具有以下一个或多个优点:具有良好的SMO抑制性;表现出良好的Hh信号通路抑制能力;具有良好的肝微粒体代谢稳定性。
    公开号:
    WO2024140595A1
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF<br/>[FR] NOUVEAUX DÉRIVÉS DE CYCLOSPORINE ET LEURS UTILISATIONS
    申请人:S&T GLOBAL INC
    公开号:WO2017200984A1
    公开(公告)日:2017-11-23
    A compound of the Formula (I) is disclosed: (I) or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification. Also described are a pharmaceutical composition comprising the same and a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, lung, and liver, and kindey diseases, and hair loss using the same.
    公开了化合物的公式(I):(I)或其药学上可接受的盐,其中符号如规范中定义。还描述了包含相同化合物的药物组合物,以及使用该药物组合物治疗或预防病毒感染、炎症、干眼症、中枢神经障碍、心血管疾病、癌症、肥胖症、糖尿病、肌肉萎缩症、肺部和肝脏疾病、肾脏疾病和脱发的方法。
  • [EN] HETEROARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE ET UTILISATIONS ASSOCIÉES
    申请人:CELGENE AVILOMICS RES INC
    公开号:WO2014144737A1
    公开(公告)日:2014-09-18
    The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.
    本发明涉及作为蛋白激酶抑制剂的化合物,这些化合物在ATP结合位点包含一个半胱氨酸残基。该发明还提供了包含一种或多种蛋白激酶抑制剂化合物的药用可接受组合物,以及使用所述组合物治疗癌症和癌的方法。
  • Anti-Cytokine Heterocyclic Compounds
    申请人:Goldberg Daniel
    公开号:US20060276496A1
    公开(公告)日:2006-12-07
    Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.
    杂环化合物及其类似物以及它们作为丝裂原活化蛋白激酶-2(MAPKAP-k2)抑制剂的用途,以及用于预防或治疗可以通过调节受试者中MAPKAP-K2活性来治疗或预防的疾病或紊乱的方法,以及包括这些MAPKAP-K2抑制剂的药物组合物和试剂盒。
  • [EN] BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS<br/>[FR] DÉRIVÉS DE STABILISATION DE BENZOPYRANE ET D'IMIDAZOLE UTILISÉS POUR LA STABILISATION DE CHAÎNES LÉGÈRES D'IMMUNOGLOBULINES AMYLOÏDOGÉNIQUES
    申请人:SCRIPPS RESEARCH INST
    公开号:WO2020205683A1
    公开(公告)日:2020-10-08
    In immunoglobulin light chain amyloidosis (AL), the unique antibody light chain (LC) protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. For treating AL patients, such as those with substantial cardiac involvement who have difficulty tolerating existing chemotherapy regimens, provided herein are small molecule compounds of Formula Ia, Formula Ib, and Formula II that are kinetic stabilizers of the native dimeric structure of full-length LCs, which compounds can slow or stop the amyloidogenicity cascade at its origin.
    在免疫球蛋白轻链淀粉样变性(AL)中,每位患者体内由单克隆浆细胞分泌的独特抗体轻链(LC)蛋白会错误折叠和/或聚集,导致器官退化的过程。为了治疗AL患者,例如那些存在严重心脏受累且难以耐受现有化疗方案的患者,本文提供了化学式Ia、化学式Ib和化学式II的小分子化合物,这些化合物是全长LC的动力学稳定剂,可以减缓或停止淀粉样生成性级联反应的起源。
  • Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design
    作者:Nicholas L. Yan、Diogo Santos-Martins、Reji Nair、Alan Chu、Ian A. Wilson、Kristen A. Johnson、Stefano Forli、Gareth J. Morgan、H. Michael Petrassi、Jeffery W. Kelly
    DOI:10.1021/acs.jmedchem.1c00339
    日期:2021.5.13
    interface between the two variable domains of the LC homodimer. We hypothesized that extending the stabilizers beyond this initially characterized binding site would improve affinity. Here, using protease sensitivity assays, we identified stabilizers that can be divided into four substructures. Some stabilizers exhibit nanomolar EC50 values, a 3000-fold enhancement over the screening hits. Crystal structures
    在免疫球蛋白轻链 (LC) 淀粉样变性中,瞬时展开或展开和蛋白水解使 LC 蛋白聚集,从而导致潜在的致命器官损伤。一种在动力学上稳定 LC 的药物可以抑制聚集;然而,LC序列是可变的并且没有天然配体,阻碍了药物开发工作。我们之前确定了高通量筛选命中,这些命中与 LC 同源二聚体的两个可变域之间的界面处的位点结合。我们假设将稳定剂延伸到最初表征的结合位点之外会提高亲和力。在这里,使用蛋白酶敏感性测定,我们确定了可分为四个亚结构的稳定剂。一些稳定剂表现出纳摩尔 EC 50值,比筛选命中提高了 3000 倍。晶体结构揭示了与筛选命中未利用的保守酪氨酸残基的关键 π-π 堆积相互作用。这些数据为开发具有改进的结合选择性和增强的物理化学性质的 LC 稳定剂提供了基础。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐